%0 Journal Article
%T What enlightenment has the development of lung cancer bone metastasis brought in the last 22 years.
%A Chen Y
%A Chen XS
%A He RQ
%A Huang ZG
%A Lu HP
%A Huang H
%A Yang DP
%A Tang ZQ
%A Yang X
%A Zhang HJ
%A Qv N
%A Kong JL
%A Chen G
%J World J Clin Oncol
%V 15
%N 6
%D 2024 Jun 24
%M 38946828
暂无%R 10.5306/wjco.v15.i6.765
%X <B>BACKGROUND: </B>Lung cancer bone metastasis (LCBM) is a disease with a poor prognosis, high risk and large patient population. Although considerable scientific output has accumulated on LCBM, problems have emerged, such as confusing research structures.<BR><B>OBJECTIVE: </B>To organize the research frontiers and body of knowledge of the studies on LCBM from the last 22 years according to their basic research and translation, clinical treatment, and clinical diagnosis to provide a reference for the development of new LCBM clinical and basic research.<BR><B>METHODS: </B>We used tools, including R, VOSviewer and CiteSpace software, to measure and visualize the keywords and other metrics of 1903 articles from the Web of Science Core Collection. We also performed enrichment and protein-protein interaction analyses of gene expression datasets from LCBM cases worldwide.<BR><B>RESULTS: </B>Research on LCBM has received extensive attention from scholars worldwide over the last 20 years. Targeted therapies and immunotherapies have evolved into the mainstream basic and clinical research directions. The basic aspects of drug resistance mechanisms and parathyroid hormone-related protein may provide new ideas for mechanistic study and improvements in LCBM prognosis. The produced molecular map showed that ribosomes and focal adhesion are possible pathways that promote LCBM occurrence.<BR><B>CONCLUSIONS: </B>Novel therapies for LCBM face animal testing and drug resistance issues. Future focus should centre on advancing clinical therapies and researching drug resistance mechanisms and ribosome-related pathways.